Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Biological Replicate ID | Conc Unit | GR50 | GEC50 | GRmax | GRinf | GR Hill Coefficient | GR_AOC | GR r2 | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LY2 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 7477.091 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0458 | -19.0433 | 1.1485 | |
| MCF 10F | NM | - | PS-1145 | IKK | NFKB | 7486.065 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0198 | -0.3050 | 1.1517 | |
| MDA-MB-175-VII | HR+ | Luminal | FTase Inhibitor I | Ftase | MAPK | 10642.142 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | 0.0208 | 0.0000 | 0.5006 | |
| BT-20 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 5903.102 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0171 | -0.1575 | 1.2557 | |
| AU565 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 7794.018 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 1.6812 | |
| LY2 | HR+ | Luminal | PS-1145 | IKK | NFKB | 7477.065 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.7891 | |
| Hs 578T | TNBC | Basal B | PS-1145 | IKK | NFKB | 7472.065 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0360 | -1.1311 | 0.9830 | |
| MDA-MB-415 | HR+ | Luminal | Baicalein | Lipoxygenase | Metabolism | 10938.072 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.5611 | |
| BT-474 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 12178.145 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | 0.0369 | 0.0948 | 0.6127 | |
| LY2 | HR+ | Luminal | L-779450 | BRAF | MAPK | 10816.149 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.4545 | |
| HCC1187 | TNBC | Basal A | LY294002 | PI3K | PI3K | 7812.029 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0475 | -56.7271 | 0.9642 | |
| Hs 578T | TNBC | Basal B | AG1024 | IGF1R | RTK | 7474.066 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | 0.0000 | -0.0022 | 2.7948 | |
| SUM1315MO2 | TNBC | Basal B | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 7528.095 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.8526 | |
| HCC1187 | TNBC | Basal A | PD184352 | MEK | MAPK | 7812.029 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | 0.0727 | 0.0526 | 0.9642 | |
| HCC1187 | TNBC | Basal A | PD184352 | MEK | MAPK | 7812.029 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | 0.0727 | 0.0526 | 0.9642 | |
| BT-474 | HER2amp | Luminal | PS-1145 | IKK | NFKB | 5905.065 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0377 | -5.6704 | 0.8461 | |
| BT-474 | HER2amp | Luminal | PS-1145 | IKK | NFKB | 5906.065 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0021 | -0.0022 | 0.6586 | |
| MDA-MB-436 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 7902.018 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0247 | -0.1948 | 1.8686 | |
| MDA-MB-175-VII | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 7499.094 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0186 | -0.2139 | 0.6407 | |
| SUM1315MO2 | TNBC | Basal B | Nilotinib | ABL | nRTK | 12428.17 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0450 | -2.6385 | 0.9724 | |
| HCC1395 | TNBC | Basal B | Cisplatin | DNA cross-linker | DNA cross-linker | 9254.049 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.8730 | |
| Hs 578T | TNBC | Basal B | Baicalein | Lipoxygenase | Metabolism | 7472.072 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 1.2269 | |
| MDA-MB-415 | HR+ | Luminal | PD184352 | MEK | MAPK | 10938.155 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0131 | -0.0082 | 0.5336 |